Real-World Data: Policy Issues Regarding their Access and Use

被引:4
作者
Basu, Anirban [1 ]
Axelsen, Kirsten [2 ]
Grabowski, David C. [3 ]
Meltzer, David O. [4 ,5 ,6 ]
Polsky, Daniel [7 ,8 ]
Ridley, David B. [9 ]
Wiederkehr, Daniel [2 ]
Philipson, Tomas J. [10 ]
机构
[1] Univ Washington, Dept Pharm, Pharmaceut Outcome Res & Policy Program, Seattle, WA 98195 USA
[2] Pfizer Inc, New York, NY USA
[3] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA
[4] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[5] Univ Chicago, Dept Econ, Chicago, IL 60637 USA
[6] Univ Chicago, Sch Publ Policy Studies, Chicago, IL 60637 USA
[7] Univ Penn, Wharton Sch, Dept Med, Philadelphia, PA 19104 USA
[8] Univ Penn, Wharton Sch, Dept Hlth Care Management, Philadelphia, PA 19104 USA
[9] Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA
[10] Univ Chicago, Harris Sch Publ Policy Studies, Chicago, IL 60637 USA
关键词
real-world data; health care decision-making; data access; regulations; quality metrics; RANDOMIZED CONTROLLED-TRIALS; CLINICAL-TRIALS;
D O I
10.1097/MLR.0000000000000603
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
As real-world data (RWD) in health care begin to cross over to the Big Data realms, a panel of health economists was gathered to establish how well the current US policy environment further the goals of RWD and, if not, what can be done to improve matters. This report summarizes these discussions spanning the current US landscape of RWD availability and usefulness, private versus public development of RWD assets, the current inherent bias in terms of access to RWD, and guiding principles in providing quality assessments of new RWD studies. Three main conclusions emerge: (1) a business case is often required to incentivize investments in RWD assets. However, access restrictions for public data assets have failed to generate a proper market for these data and hence may have led to an underinvestment of public RWDs; (2) Very weak empirical evidence exist on for-profit entities misusing public RWD data entities to further their own agendas, which is the basis for supporting access restrictions of public RWD data; and (3) perhaps developing standardized metrics that could flag misuse of RWDs in an efficient way could help quell some of the fear of sharing public RWD assets with for-profit entities. It is hoped that these discussions and conclusions would pave the way for more rigorous and timely debates on the greater availability and accessibility of RWD assets.
引用
收藏
页码:1038 / 1044
页数:7
相关论文
共 15 条
[1]   Understanding randomised controlled trials [J].
Akobeng, AK .
ARCHIVES OF DISEASE IN CHILDHOOD, 2005, 90 (08) :840-844
[2]  
[Anonymous], 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18430
[3]  
[Anonymous], BMC MED RES METHODOL
[4]   Welfare implications of learning through solicitation versus diversification in health care [J].
Basu, Anirban .
JOURNAL OF HEALTH ECONOMICS, 2015, 42 :165-173
[5]  
Edwards T-QH, 2013, CLIN RES PULMONOL, P1
[6]  
Emery G, 2012, PROSTATE CANC SURG F
[7]  
Feinberg L., 2012, Public Policy Aging Report, V24, P97, DOI DOI 10.1093/PPAR/PRU027
[8]   Randomized controlled trials: Do they have external validity for patients with multiple comorbidities? [J].
Fortin, M ;
Dionne, J ;
Pinbo, GV ;
Gignac, J ;
Almirall, J ;
Lapointe, L .
ANNALS OF FAMILY MEDICINE, 2006, 4 (02) :104-108
[9]   Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report [J].
Garrison, Louis P., Jr. ;
Neumann, Peter J. ;
Erickson, Pennifer ;
Marshall, Deborah ;
Mullins, Daniel .
VALUE IN HEALTH, 2007, 10 (05) :326-335
[10]   Where Is the American College of Cardiology Heading? A PINNACLE Registry Case Study [J].
Jacobovitz, Shalom .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (02) :226-228